AI News Sentiment & Analysis
Collegium Pharmaceutical, Inc. (COLL) — AI News Sentiment & Analysis
4 recent AI analyses of Collegium Pharmaceutical, Inc. (COLL) stock news and press releases, with sentiment and confidence scoring updated continuously.
Collegium Pharmaceutical Cuts Full-Year Guidance on Weak Pain Portfolio Despite Strong ADHD Segment Growth
BearishEarnings ReleaseThe lowered full-year 2026 revenue and EBITDA guidance, driven by specific segment weakness, is likely to lead to analyst downgrades and immediate pressure on the stock. (Timing: Short-term, within the next few days as analysts update models and the market reacts.)Aug 6, 2026Collegium Reports Strong Q1 2026 Results, Reaffirms Guidance, and Advances AZSTARYS Acquisition
BullishEarnings ReleaseStrong Q1 2026 earnings report, reaffirmation of current business guidance, and positive progress towards closing the AZSTARYS acquisition. (Timing: Immediate (Q1 results), Q2 2026 (acquisition close).)May 7, 2026Collegium's AZSTARYS Acquisition Draws Market Concern Over Increased Debt
BearishCollegium's definitive agreement to acquire AZSTARYS for $650 million cash, with potential milestones up to $135 million, alongside the market's negative response to the deal's financing structure. (Timing: The transaction is expected to close in the second quarter of 2026, with the financial impacts and integration challenges becoming clearer from the second half of 2026.)Mar 19, 2026Collegium Pharmaceutical Partners with Paris Hilton for ADHD Awareness Campaign
BullishCollegium Pharmaceutical announced a partnership with Paris Hilton to promote ADHD awareness. This partnership could enhance the company's visibility and potentially drive demand for its ADHD treatment, JORNAY PM. The campaign aims to normalize conversations around ADHD, which may unlock value for the company.Mar 3, 2026
Want the full picture?
These are AI analyses of recent press releases. Sign up to see full reasoning, confidence details, and get real-time alerts.
Sign Up for FreeFrequently Asked Questions
Is Collegium Pharmaceutical, Inc. (COLL) bullish or bearish right now?
AI Sentiment on COLL: 2 Bullish, 2 Bearish.
What was the latest AI analysis for Collegium Pharmaceutical, Inc. (COLL)?
The latest analysis was published on 8/6/2026 with the headline: "Collegium Pharmaceutical Cuts Full-Year Guidance on Weak Pain Portfolio Despite Strong ADHD Segment Growth".
How does Bekodia analyze Collegium Pharmaceutical, Inc. (COLL) stock?
Bekodia uses advanced AI models to process Collegium Pharmaceutical, Inc. (COLL) press releases and news in real-time, extracting sentiment, confidence scores, and key catalysts while filtering out market noise.